---
title: 'Treosulfan compared to busulfan in allogeneic haematopoietic stem cell transplantation
  for myelofibrosis: a registry-based study from the Chronic Malignancies Working
  Party of the EBMT'
date: '2024-03-16'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38491198/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240317180557&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: We aimed to compare outcomes following treosulfan (TREO) or busulfan
  (BU) conditioning in a large cohort of myelofibrosis (MF) patients from the EBMT
  registry. A total of 530 patients were included; 73 received TREO and 457 BU (BU
  ≤ 6.4 mg/kg in 134, considered RIC, BU > 6.4 mg/kg in 323 considered higher dose
  (HD)). Groups were compared using adjusted Cox models. Cumulative incidences of
  engraftment and acute GVHD were similar across the 3 groups. The TREO group had
  significantly better OS ...
disable_comments: true
---
We aimed to compare outcomes following treosulfan (TREO) or busulfan (BU) conditioning in a large cohort of myelofibrosis (MF) patients from the EBMT registry. A total of 530 patients were included; 73 received TREO and 457 BU (BU ≤ 6.4 mg/kg in 134, considered RIC, BU > 6.4 mg/kg in 323 considered higher dose (HD)). Groups were compared using adjusted Cox models. Cumulative incidences of engraftment and acute GVHD were similar across the 3 groups. The TREO group had significantly better OS ...